Universitat Pompeu Fabra

Universitat Pompeu Fabra
Plaça de la Mercè
E-08002 Barcelona
Spain
www.upf.edu

The Universitat Pompeu Fabra (UPF) will participate in the project through the Research Unit on Biomedical Informatics (GRIB) , which is a joint research unit of both the UPF and the Municipal Institute of Medical Research (IMIM) in Barcelona. IMIM is also affiliated to the Universitat Pompeu Fabra as university institute and many GRIB members are teaching staff of this university.

The Research Unit on Biomedical Informatics is currently composed of more than 60 members, coordinated by Dr. Ferran Sanz. The unit is organized in 7 labs and a management team that correspond to the main activity lines of our group: Computational Genomics, Structural Bioinformatics, Computational Biochemistry and Biophysics, Chemogenomics, Computed-assisted Drug Design, Complex Systems and Integrative Biomedical Informatics. The unit has a wide experience in the participation and coordination of research projects funded by the European Commission. In the last years, the unit has participated in 14 European projects. On the other hand, GRIB is involved in pre and postgraduate teaching of the bioinformatics and biocomputation disciplines within the School of Health and Life Sciences of UPF.

Key staff involved:

Ferran Sanz
Professor of Biostatistics and Biomedical Informatics at the Universitat Pompeu Fabra (UPF) of Barcelona. Director of the Research Unit on Biomedical Informatics (GRIB) of the IMIM and the UPF. Author of more than 80 articles published in SCI indexed journals. Mentor of 16 PhD thesis. Coordinator of several EC-funded initiatives. Scientific reviewer and expert for national and international bodies. President of the European Federation for Medicinal Chemistry from 2003 to 2005, currently member of its Executive Committee as Past-President.

Manuel Pastor
Manuel Pastor is the head of the PharmacoInformatics Group (PhI). The main research lines of the PhI aim to improve current methodologies used for in silico prediction systems and multi-level modeling, at different areas related with drug discovery and development. Other research lines of the laboratory are related with the application of structural and simulation methods to the investigation of the molecular mechanisms involved in the pharmacological effects of antipsychotic drugs. The PhI participated in diverse international, EU funded projects (eg. Link3D, Cancergrid, eTOX, OpenPHACTS) in collaboration with pharmaceutical companies and academic institutions, aiming to improved the current state-of-the-art of drug design and development.

Sponsored by